e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Astellas Pharma Inc
(OP:
ALPMY
)
12.25
+0.28 (+2.31%)
Streaming Delayed Price
Updated: 12:21 PM EST, Nov 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
23,452
Open
12.12
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
11.97
Today's Range
12.12 - 12.30
52wk Range
8.370 - 12.58
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
↗
November 12, 2025
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
Via
Benzinga
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
↗
October 18, 2025
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with bladder cancer.
Via
Investor's Business Daily
Performance
YTD
+27.3%
+27.3%
1 Month
+17.3%
+17.3%
3 Month
+9.5%
+9.5%
6 Month
+33.8%
+33.8%
1 Year
+14.0%
+14.0%
More News
Read More
Why Is Taysha Gene Therapies Stock Falling Friday?
↗
October 17, 2025
Via
Benzinga
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
↗
August 12, 2025
Via
Benzinga
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study
↗
July 10, 2025
Via
Benzinga
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
↗
March 18, 2025
Via
Benzinga
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
↗
February 11, 2025
Via
Benzinga
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise
↗
January 03, 2025
Via
Benzinga
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
↗
December 31, 2024
Via
Benzinga
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
↗
October 29, 2024
Via
The Motley Fool
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
↗
October 16, 2024
Via
Benzinga
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
↗
September 19, 2024
Via
Investor's Business Daily
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
↗
August 05, 2024
Via
Benzinga
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
↗
February 22, 2024
Via
Talk Markets
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
↗
December 31, 2023
Via
Talk Markets
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
↗
December 29, 2023
Via
Benzinga
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
↗
October 22, 2023
Via
Investor's Business Daily
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
↗
October 05, 2023
Via
Benzinga
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years
↗
September 24, 2023
Via
The Motley Fool
Why Is Seagen Stock Trading Higher Today?
↗
September 22, 2023
Via
Benzinga
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
↗
September 22, 2023
Via
Investor's Business Daily
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
↗
September 20, 2023
Via
Benzinga
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Via
MarketBeat
Topics
Economy
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin
↗
August 07, 2023
Via
Investor's Business Daily
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
↗
July 07, 2023
Via
Benzinga
Frequently Asked Questions
Is Astellas Pharma Inc publicly traded?
Yes, Astellas Pharma Inc is publicly traded.
What exchange does Astellas Pharma Inc trade on?
Astellas Pharma Inc trades on the OTC Traded
What is the ticker symbol for Astellas Pharma Inc?
The ticker symbol for Astellas Pharma Inc is ALPMY on the OTC Traded
What is the current price of Astellas Pharma Inc?
The current price of Astellas Pharma Inc is 12.25
When was Astellas Pharma Inc last traded?
The last trade of Astellas Pharma Inc was at 11/14/25 12:21 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.